Silence Therapeutics (SLN) Tax Provisions (2024 - 2026)
Silence Therapeutics (SLN) posted Tax Provisions of $1000.0 for Q3 2025, down 90.0% sequentially from $10000.0 in Q2 2025, and down 97.96% YoY from $49000.0 in Q3 2024.
Powered by 
Analysis
Silence Therapeutics (SLN) Tax Provisions (2024 - 2026) Analysis & Trends
Silence Therapeutics has reported Tax Provisions for 2 years, with the latest figure at $1000.0 in Q3 2025.
- Quarterly Tax Provisions fell 97.96% year-over-year to $1000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $11000.0 (up 100.1% YoY) and the FY2025 annual result came in at $11000.0, up 100.1% from the prior year.
- Tax Provisions slipped to $1000.0 in Q3 2025 per SLN's latest filing, from $10000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $244000.0 in Q1 2024 and troughed at -$11.6 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Silence Therapeutics | 690.60 Mn | 618.50 Mn | - | 1,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Dec 31, 2025 | -22.16 Mn |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Dec 31, 2024 | -11.64 Mn |
| Sep 30, 2024 | 49,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 244,000.00 |